Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)-Reference-Cited by-同舟云学术

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)

Published:2016-05-18 Issue:8 Volume:18 Page:775-782
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ji L.-N.¹,Pan C.-Y.²,Lu J.-M.²,Li H.³,Zhu D.-L.⁴,Li Q.⁵,Li Q.-F.⁶,Peng Y.-D.⁷,Tian H.-M.⁸,Yao C.⁹,Zhao Z.-G.¹⁰,Wang L.¹¹,Wang B.-H.¹¹,

Affiliation:

1. Department of Endocrinology; Peking University People's Hospital; Beijing China

2. Department of Endocrinology; Chinese PLA General Hospital; Beijing China

3. Department of Endocrinology; Sir Run Run Shaw Hospital, Zhejiang University Medical College; Hangzhou China

4. Department of Endocrinology; Nanjing Drum Tower Hospital, Nanjing University Medical School; Nanjing China

5. Department of Endocrinology and Metabolism; Second Affiliated Hospital of Harbin Medical University; Harbin China

6. Department of Endocrinology; First Affiliated Hospital of Chongqing Medical University; Chongqing China

7. Department of Endocrinology; Shanghai First People's Hospital; Shanghai China

8. Department of Endocrinology; West China Hospital, Sichuan University; Chengdu China

9. Department of Endocrinology; Peking University First Hospital; Beijing China

10. Department of Endocrinology; Zhengzhou Yihe Hospital; Zhengzhou China

11. Novartis Pharmaceuticals (China); Shanghai China

Funder

Novartis Pharmaceuticals (China)

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12667/fullpdf

Reference37 articles.

1. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?;Zinman;Am J Med,2011

2. World Health Organization Global status report on noncommunicable diseases 2014 http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf

3. Prevalence of diabetes among men and women in China;Yang;N Engl J Med,2010

4. Standards of medical care in diabetes-2015 abridged for primary care providers;American Diabetes Association;Clin Diabetes,2015

5. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin for preventing the progression of chronic kidney disease;Cochrane Database of Systematic Reviews;2024-06-04

2. PERSPECTIVES OF CLINICAL EXPERTS ON THE CURRENT USAGE PATTERNS AND THE PREFERENCE OF VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES;Innovare Journal of Medical Sciences;2024-03-12

3. A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study);Journal of Diabetes Research;2024-01-05

4. SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson’s disease;Acta Pharmacologica Sinica;2023-09-07

5. Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study;Cureus;2023-09-01